Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com.
Detecting Endometrial Cancer by Blood Spectroscopy: A Diagnostic Cross-Sectional Study
27 Pages Posted: 8 May 2020
More...Abstract
Background: Endometrial cancer is the sixth most common cancer in women with a rising incidence worldwide. Current approaches for the diagnosis and screening of endometrial cancer are invasive, expensive and of moderate diagnostic accuracy, limiting their clinical utility. There is a need for cost-effective and minimally invasive biomarkers to facilitate the early detection and timely management of endometrial cancer.
Methods: We analysed blood plasma samples in a cross-sectional diagnostic accuracy study of women with endometrial cancer(n=342), its precursor lesion atypical hyperplasia(n=68) and healthy controls(n=242, total n=652) using attenuated total reflection-Fourier transform infrared(ATR-FTIR) spectroscopy and machine learning algorithms.
Findings : We show that blood-based infrared spectroscopy has the potential to detect endometrial cancer with 87% sensitivity and 78% specificity. Its accuracy is highest for type I endometrial cancer, the most common subtype, and for atypical hyperplasia, with sensitivities of 91% and 100%, and specificities of 81% and 88%, respectively.
Interpretation: Our large-cohort study shows that a simple blood test could enable the early detection of endometrial cancer of all stages in symptomatic women and provide the basis of a screening tool in high-risk groups. Such a test will not only differentially diagnose endometrial cancer but also detect its precursor lesion atypical hyperplasia, the early recognition of which may allow fertility-sparing management and cancer prevention.
Funding Statement: The authors were supported by the Rosemere Cancer Foundation, CAPES–Brazil, Wellcome Trust, Wellbeing of Women, MRC, NIHR and the Department of Health. The views expressed are those of the authors and not necessarily of the funders.
Declaration of Interests: The authors declare no potential conflicts of interest.
Ethics Approval Statement: All women gave written, informed consent to participate and donated their clinical data and blood samples for future research. Ethical approval was obtained as follows: Weight loss study (North West Research Ethics Committee ref. 12/NW/0050), PROTEC study (Cambridge East Research Ethics Committee ref. 15/EE/0063), PREMIUM study (North West Research Ethics Committee ref. 14/NW/1236), Metformin study (North West Research Ethics Committee ref. 11/NW/0442), PETALS study (NRES Committee North West – Lancaster ref. 15/NW/0733), DETECT study (North West Research Ethics Committee - Greater Manchester 16/NW/0660), and East of England – Cambridge Central Research Ethics Committee ref. 16/EE/0010.
Keywords: blood diagnostics; endometrial cancer; screening; spectroscopy
Suggested Citation: Suggested Citation